Pulmonx to Participate in September Investor Conferences
Pulmonx (NASDAQ:LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4 at 1:30 PM PT in Boston, with a webcast available. Additionally, management will attend the Lake Street Best Ideas Growth Conference on September 11 in New York for one-on-one meetings. Investors can access the Wells Fargo fireside chat webcast through Pulmonx's investor relations website.
Pulmonx (NASDAQ:LUNG), azienda leader nei trattamenti minimamente invasivi per le malattie polmonari, ha annunciato la sua partecipazione a due conferenze per investitori in programma a settembre 2025.
L'azienda prenderà parte a un fireside chat al Wells Fargo Healthcare Conference il 4 settembre alle 13:30 PT a Boston, con webcast disponibile. Inoltre, il management sarà presente al Lake Street Best Ideas Growth Conference l'11 settembre a New York per incontri one-to-one. Gli investitori possono seguire il webcast del fireside chat di Wells Fargo tramite il sito investor relations di Pulmonx.
Pulmonx (NASDAQ:LUNG), líder en tratamientos mínimamente invasivos para enfermedades pulmonares, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2025.
La compañía participará en un fireside chat en el Wells Fargo Healthcare Conference el 4 de septiembre a las 13:30 PT en Boston, con webcast disponible. Además, la dirección asistirá al Lake Street Best Ideas Growth Conference el 11 de septiembre en Nueva York para reuniones one-to-one. Los inversores pueden acceder al webcast del fireside chat de Wells Fargo a través del sitio de relaciones con inversores de Pulmonx.
Pulmonx (NASDAQ:LUNG)는 최소침습 폐 질환 치료 분야의 선두주자로, 2025년 9월 개최되는 두 건의 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 9월 4일 오후 1시 30분(PT) 보스턴에서 열리는 Wells Fargo Healthcare Conference의 파이어사이드 채팅에 참석하며 웹캐스트가 제공됩니다. 또한 경영진은 9월 11일 뉴욕에서 열리는 Lake Street Best Ideas Growth Conference에 참석해 일대일 미팅을 진행할 예정입니다. 투자자들은 Pulmonx 투자자 관계 웹사이트를 통해 Wells Fargo 파이어사이드 채팅의 웹캐스트를 시청할 수 있습니다.
Pulmonx (NASDAQ:LUNG), leader des traitements pulmonaires mini-invasifs, a annoncé sa participation à deux conférences investisseurs prévues en septembre 2025.
L'entreprise prendra part à un fireside chat lors de la Wells Fargo Healthcare Conference le 4 septembre à 13h30 PT à Boston, avec webdiffusion disponible. De plus, la direction assistera à la Lake Street Best Ideas Growth Conference le 11 septembre à New York pour des rencontres individuelles. Les investisseurs peuvent accéder au webdiffusion du fireside chat Wells Fargo via le site relations investisseurs de Pulmonx.
Pulmonx (NASDAQ:LUNG), ein führendes Unternehmen für minimalinvasive Behandlungen von Lungenerkrankungen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am 4. September um 13:30 Uhr PT in Boston an einem Fireside Chat auf der Wells Fargo Healthcare Conference teilnehmen; ein Webcast wird verfügbar sein. Außerdem wird das Management am 11. September in New York an der Lake Street Best Ideas Growth Conference für Einzelgespräche teilnehmen. Investoren können den Webcast des Wells Fargo Fireside Chats über die Investor-Relations-Website von Pulmonx abrufen.
- None.
- None.
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the following investor conferences:
Wells Fargo Healthcare Conference
Format: Fireside Chat and 1x1 meetings
Date: Thursday, September 4 at 1:30 pm PT/ 4:30 pm ET
Location: Boston, MA
Webcast Link: Click here
Lake Street Best Ideas Growth (BIG9) Conference
Format: 1x1 meetings
Date: Thursday, September 11
Location: New York, NY
A live and archived webcast of the fireside chat will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When is Pulmonx (LUNG) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access Pulmonx's Wells Fargo Conference presentation?
What type of presentation will Pulmonx give at the Wells Fargo Healthcare Conference?
When is Pulmonx participating in the Lake Street BIG9 Conference 2025?
